Search - tctmd.com

Displaying 221 - 240 of 245

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2016

我对 2016 年 TCT 的总结：惊喜、假设和赠品

Shelley Wood

November 07, 2016

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Opinion Editor's Corner TCT 2016

Con Qué Me Quedo de TCT 2016: Sorpresas, Presuposiciones y Revelaciones

Shelley Wood

November 07, 2016

Presentation TCT 2016

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran

November 01, 2016

Presentation TCT 2016

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx

November 01, 2016

Presentation TCT 2016

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

Presenter: David P. Faxon, C. Michael Gibson, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: David P. Faxon, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Davide Capodanno

November 01, 2016

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger

November 01, 2016

News Daily News

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

Todd Neale

October 18, 2016

News Daily News

Increased Risk of In-Hospital Complications, Including Mortality, Among A-fib Patients Undergoing PCI

Michael O'Riordan

August 24, 2016

News Daily News

数据缺口：使用新抗凝血剂的房颤患者 PCI 最佳策略未知

L.A. McKeown

August 17, 2016

News Daily News

Data Gap: Best Strategy Unknown for A-Fib Patients on Newer Anticoagulants Who Need PCI

L.A. McKeown

August 17, 2016

News Daily News

Ausencia de Datos: No Sabemos Cuál es la Mejor Estrategia para el Manejo de Pacientes con FA a Tratamiento con los Últimos Anticoagulantes y que Necesitan una PCI

L.A. McKeown

August 17, 2016

News Daily News

Publica la AHA declaración sobre los desfibriladores portátiles y advierte que los datos sobre su eficacia son limitados

Michael O'Riordan

March 31, 2016

Advertisement

我对 2016 年 TCT 的总结：惊喜、假设和赠品

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Con Qué Me Quedo de TCT 2016: Sorpresas, Presuposiciones y Revelaciones

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

Increased Risk of In-Hospital Complications, Including Mortality, Among A-fib Patients Undergoing PCI

数据缺口：使用新抗凝血剂的房颤患者 PCI 最佳策略未知

Data Gap: Best Strategy Unknown for A-Fib Patients on Newer Anticoagulants Who Need PCI

Ausencia de Datos: No Sabemos Cuál es la Mejor Estrategia para el Manejo de Pacientes con FA a Tratamiento con los Últimos Anticoagulantes y que Necesitan una PCI

Publica la AHA declaración sobre los desfibriladores portátiles y advierte que los datos sobre su eficacia son limitados

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content